Immusmol SAS

Immusmol SAS is a CRO that provides preclinical testing services specializing in the field of cancer immunotherapy. Utilizing highly accurate cell assays, animal models, and advanced spatial biology analysis,Supports R&D for pharmaceutical and biotech companies worldwideThis article provides a detailed introduction to Immusmol SAS's features, its available disease models, and examples of non-clinical studies. Please use this as a reference when choosing a contract research organization.

Characteristics of Immusmol SAS's Non-clinical Testing Contract Services

Compatible with a wide range of cell-based immune assessment assays

Immusmol SAS conducts a wide range of in vitro (cell-level) tests specifically for cancer immunotherapy. Typical examples include:Immune checkpoint inhibitor assays (PD-1/PD-L1, CTLA-4, etc.), antibody-dependent cell-mediated cytotoxicity (ADCC), tumoricidal assays, and the like. These tests allow for precise evaluation of the interaction between immune cells and tumor cells, as well as therapeutic effects. Furthermore, we can also support mixed lymphocyte reactions (MLR), macrophage function assays, and cytokine release assays. The flexibility to customize based on research themes and development stages is a major strength of Immusmol SAS's in vitro assays.

One-stop support from test design to data analysis

Immusmol SAS, not only for cell testing,We have established a system to complete in vivo (animal model) studies and human sample analysis in-house. In particular, the evaluation of immune responses using syngeneic tumor models is highly valued for its ability to reproducibly verify the effects of anticancer drugs and immune checkpoint inhibitors. We also focus on translational research with a view to clinical application, providing comprehensive research support by combining the latest technologies such as biomarker discovery and spatial biology analysis. As a "CRO that can handle everything from study design to analysis," we have earned the trust of bio-companies worldwide.

An example of a disease model held by Immusmol SAS

When selecting a contract research organization (CRO), the variety and reliability of their disease models are important decision-making factors. Immusmol SAS specializes in cancer immunotherapy research and offers a diverse range of models, including syngeneic tumor models where the immune system functions. Here, we will present examples of representative models and outline their characteristics and use cases.

Immunological response evaluation model using mice (syngeneic tumor model)

One of Immusmol SAS's representative models is the syngeneic tumor model in mice, which can be evaluated with a functioning immune system. In this model, syngeneic tumor cells are transplanted into inbred mice, allowing observation of the interaction between tumors and immune cells under physiologically relevant conditions. For immune checkpoint inhibitors, CAR-T, NK cell therapies, etc.,It is suitable for verifying the effectiveness of therapies that utilize the immune system. In Immusmol SAS, it is used for evaluating major immunotherapies such as anti-CTLA-4 antibodies and anti-PD-1/PD-L1 antibodies, and changes in the immune microenvironment can be understood through multiplex immunohistochemistry and spatial analysis.

Biomarker Discovery Model Using Human Samples (Translational Research)

Immusmol SAS focuses on translational research using not only animal models but also human-derived samples. By analyzing clinical samples such as tumor tissue and blood, they support the discovery of new cancer treatment targets and biomarkers. This enables them to assist in the design and hypothesis testing of translational research, bridging the gap from preclinical stages to clinical trials. They can visualize patient-specific immune responses and treatment efficacy variations that are difficult to discern with animal studies alone.It is useful as a practical validation model for the development of cancer immunotherapy.

Immusmol SAS's Non-clinical Trial Cases

Immune checkpoint inhibitor efficacy verification trial

Immusmol SAS is conducting preclinical studies of immune checkpoint inhibitors using syngeneic tumor mouse models. A representative example is the evaluation of the efficacy of anti-PD-1 and anti-PD-L1 antibody therapies using a colorectal cancer model (MC38). In addition to the tumor growth inhibitory effect,We are investigating the mechanisms of treatment response by analyzing immune cell infiltration and cytokine dynamics.

Translational research for biomarker discovery

At Immusmol SAS, we are also advancing the exploration of novel biomarkers through translational research using clinical samples. We analyze tumor tissues and blood samples to support prediction of immunotherapy efficacy and identification of therapeutic targets. By combining spatial biology and single-cell analysis technologies,You can accurately grasp the immune cell dynamics within the tumor microenvironment (TME). These analysis results are utilized as important findings to improve the precision of clinical applications and treatment strategies.

Immusmol SAS Company Information

Immusmol SAS is a preclinical and translational research CRO specializing in the development of cancer immunotherapies. Based in Bordeaux, France, we support the research and development efforts of pharmaceutical companies and bioventures not only in Europe but also globally, including North America, Japan, and South Korea.